EN DE
Watch Medtecs International Corporation Ltd DRC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medtecs International Corporation Ltd (9103) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Medtecs International Corporation Ltd stock TWD 5.19, price TWD 5.06, upside +2.6%, quality 54 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0009103002

MI Medtecs International Corporation Ltd logo Thin data Nov 10, 2026

Medtecs International Corporation Ltd

9103 · TW
Fairly valued, in an uptrend

The stock costs about what our calculation considers fair.

Low debt
Last quarter vs. a year ago: revenue +16%, profit +160%.
Fair value 5.19 TWD · Fairly valued
Quality 54/100
Mixed vs. peers (5/10)
Weak Growth (revenue 5y −27.8 %/yr in USD)
Loss-making · -5.3% net margin (TTM)
Negative free cash flow
Narrow moat 14/100 · thin data
Thin data
Estimate
Watch Medtecs International Corporation Ltd DRC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

25.45 TWD 4.04 TWD Fair Value 5.19 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 4.04 TWD – 25.45 TWD · fair‑value band 3.90 TWD – 6.49 TWD · the 5.06 TWD price screens below the 5.19 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Medtecs International Corporation Ltd DRC in your weekly email

Every Wednesday you see whether Medtecs International Corporation Ltd DRC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medtecs International Corporation Limited, an integrated healthcare services provider, manufactures and distributes medical consumables for healthcare distributors, pharmaceutical companies, and hospital groups. It operates through Manufacturing, Hospital, and Distribution and Others segments.

Show moreShow less

The Manufacturing segment produces and sub-contracts a range of medical consumables, including patients' apparel, disposable surgical masks, boot covers and surgical gowns, underpads, adult diapers, crochet blankets, bed linens, and medical bandages.

Its Hospital Services segment offers laundry and leasing services to hospitals that outsource its non-critical functions. The Distribution segment markets Medtecs-branded medical consumables to hospitals, pharmacies, and other end users, as well as through online channels.

This segment also supplies other branded medical supplies and equipment comprising wheelchairs, syringes, nebulizers, and blood pressure monitors.

In addition, the company manufactures, leases, trades in, and sells woven and knitted medical textile products; provides personal protective equipment, nitrile gloves, garters, and other garment products, as well as logistics and procurement services; trades in hospital textiles and garments, pillow cases, bed sheets, gowns, and other apparel products; sells hygiene products; and engages in subleasing activities.

It operates in the Philippines, Singapore, Cambodia, China, Bermuda, Taiwan, Luxembourg, the United States, the United Kingdom, and internationally. Medtecs International Corporation Limited was founded in 1989 and is headquartered in Taipei, Taiwan.

Stock analysis

Medtecs International Corporation Ltd (9103) currently trades at 5.06 TWD, while our estimate is 5.19 TWD, so the stock looks roughly fairly valued today (gap 2.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 3.90 TWD (bear) to 6.49 TWD (bull), the price of 5.06 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Medtecs International Corporation Ltd DRC reported revenue of $78.4M in FY2025 versus $144M in FY2021, a compound −14.1%/yr. Reported net income was −$4.8M in FY2025.

Key figures

Market cap 2.7B TWD (≈ $83.7M) Micro · P/S ratio 35.3 · EPS (TTM) −0.2600 TWD · Net margin −6.1% · Return on equity −4.3% · Return on assets (EBIT) −9.5% (5-year average) · Operating margin 1.4% · Revenue (TTM) $84.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 3%, 9103 screens cheaper than that median.

Fair Value

Bear 3.90 TWD Fair Value 5.19 TWD Bull 6.49 TWD
Price 5.06 TWD · Upside +2.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 54/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 96
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 82
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 62
How calm the share price moves, does not count
Price momentum 47
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 33
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+44.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−27.8%
Start year 2020 (pandemic). Over 10 years: +2.4% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
34.1% (2020) → −8.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 9103, get fair value alerts →

Compare Medtecs International Corporation Ltd DRC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 198 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 54 · Below median
Fair Value upside +2.4% · Above median
Profitability
Return on assets −3.3% · Bottom 25%
Net margin (12 months) −5.3% · Bottom 25%
Operating margin (12 months) 1.4% · Below median
Growth and dividend
Revenue growth (quarter YoY) 16.1% · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.83× · Cheapest 25%
P/S (12 months) 0.99× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)37 · sector 18
FUTURE (revenue growth)81 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.43 $131.27 +45% vs 9103
EssilorLuxottica Société anonyme EL €190.60 €196.22 +3% vs 9103
Intuitive Surgical, Inc ISRG $460.56 $353.90 −23% vs 9103
Medline Inc MDLN $40.71 $28.59 −30% vs 9103
Alcon Inc ALC CHF 61.22 CHF 34.06 −44% vs 9103
Becton, Dickinson and Company BDX $215.25 $97.80 −55% vs 9103
Straumann Holding STMN CHF 105.45 CHF 45.50 −57% vs 9103
West Pharmaceutical Services, Inc WST $413.09 $139.22 −66% vs 9103
Sartorius Stedim Biotech S.A DIM €226.20 €54.82 −76% vs 9103
Sartorius Aktiengesellschaft SRT €229.00 €42.50 −81% vs 9103

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medtecs International Corporation Ltd DRC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medtecs International Corporation Ltd DRC Fair Value". https://www.fairvalue-calculator.com/stock/9103

Frequently asked questions

Is Medtecs International Corporation Ltd (9103) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 5.19 TWD versus a price of 5.06 TWD, about +3% upside (fairly valued).
What is the fair value of 9103?
Our estimate for Medtecs International Corporation Ltd is 5.19 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 5.06 TWD.
What is the quality score of 9103?
Medtecs International Corporation Ltd has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medtecs International Corporation Ltd (9103)?
Our calculated price target is the estimate of 5.19 TWD (as of Nov 10, 2026). Cautious scenario 3.90 TWD, optimistic scenario 6.49 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Medtecs International Corporation Ltd DRC stock forecast for 2026?
Our estimate puts fair value at 5.19 TWD, about +3% upside versus a price of 5.06 TWD (fairly valued). Cautious scenario 3.90 TWD, optimistic scenario 6.49 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Medtecs International Corporation Ltd (9103)?
Medtecs International Corporation Ltd reported trailing-twelve-month revenue of about $84.8M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Medtecs International Corporation Ltd (9103)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medtecs International Corporation Ltd it is 5.19 TWD per share (as of Nov 10, 2026), against a price of 5.06 TWD.
Is Medtecs International Corporation Ltd DRC stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 9103 trades below its calculated fair value: price 5.06 TWD, fair value 5.19 TWD, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9103?
No. The price is what the market pays today (5.06 TWD); the fair value is what the company's own numbers justify (5.19 TWD). For Medtecs International Corporation Ltd the two are 0.1300 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Medtecs International Corporation Ltd DRC worth?
The market values Medtecs International Corporation Ltd at about 2.7B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 5.06 TWD; our models calculate a fair value of 5.19 TWD per share.
What do the bullish and bearish scenarios say about 9103?
Our models span a range for Medtecs International Corporation Ltd: cautious scenario 3.90 TWD, base 5.19 TWD, optimistic 6.49 TWD per share (as of Nov 10, 2026, price 5.06 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medtecs International Corporation Ltd (9103)?
Balance-sheet figures for Medtecs International Corporation Ltd (as of Nov 10, 2026): return on equity −4.3%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 9103 from its 52-week high?
Medtecs International Corporation Ltd trades at 5.06 TWD, about 28% below its 52-week high of 7.02 TWD and 16% above the low of 4.36 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 5.19 TWD is for.
Which stocks are comparable to Medtecs International Corporation Ltd DRC?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medtecs International Corporation Ltd DRC stock attractive at the current price?
The data as of Nov 10, 2026: price 5.06 TWD, calculated fair value 5.19 TWD (+3%), Quality Score 54/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Medtecs International Corporation Ltd currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medtecs International Corporation Ltd (9103)?
The closing price on Nov 10, 2026 was 5.06 TWD. Our estimate is 5.19 TWD, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medtecs International Corporation Ltd DRC right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Medtecs International Corporation Ltd

How large is the market capitalisation of Medtecs International Corporation Ltd (9103)?
The market capitalisation of Medtecs International Corporation Ltd is 2.7B TWD (≈ $83.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medtecs International Corporation Ltd (9103)?
The price-to-sales ratio of Medtecs International Corporation Ltd is 35.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medtecs International Corporation Ltd (9103)?
Earnings per share at Medtecs International Corporation Ltd are −0.2600 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medtecs International Corporation Ltd (9103)?
The net margin of Medtecs International Corporation Ltd is −6.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medtecs International Corporation Ltd (9103)?
The return on equity (ROE) of Medtecs International Corporation Ltd is −4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medtecs International Corporation Ltd (9103)?
On an EBIT basis the return on assets of Medtecs International Corporation Ltd is −9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medtecs International Corporation Ltd (9103)?
The operating margin of Medtecs International Corporation Ltd is 1.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medtecs International Corporation Ltd (9103)?
Revenue at Medtecs International Corporation Ltd is growing +16.1% versus a year earlier (3y avg +11.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medtecs International Corporation Ltd (9103)?
Earnings per share at Medtecs International Corporation Ltd are growing +160% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medtecs International Corporation Ltd (9103) generate?
The free cash flow of Medtecs International Corporation Ltd is −$5.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medtecs International Corporation Ltd (9103) carry?
The net debt of Medtecs International Corporation Ltd is $6.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medtecs International Corporation Ltd DRC in the live analysis

One click puts Medtecs International Corporation Ltd DRC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.